Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05941234

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-03-13

120

Participants Needed

1

Research Sites

147 weeks

Total Duration

On this page

Sponsors

F

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Lead Sponsor

O

Oslo University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study aims at: 1. Perform a multilayer analysis relying on tight integration of in-depth multi-omics approaches with clinical data to discover immune markers, with attention to age and sex differences, predicting prognosis and defining key life/environmental elements, to guide AI-driven personalised treatments and ensure improved care and QoL of glioblastoma patients. 2. To deepen glioblastoma knowledge through the study of glioblastoma stem cell cultures and to assess the sensitivity of glioblastoma stem cell cultures to a number of chemotherapeutics in different experimental conditions. 3. To create a comprehensive, stakeholder-generated guidelines for the ethical use of patient data for artificial intelligence-assisted prediction systems in glioblastoma, including an online, easily accessible patient information brochure to increase patient empowerment in the field.

CONDITIONS

Official Title

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Radiological diagnosis of supratentorial glioblastoma or first recurrence confirmed by prior surgery
  • Candidate for neurosurgery for glioblastoma at Fondazione Policlinico Gemelli IRCCS
  • Age 18 years or older
  • Provided written informed consent to participate in the study
Not Eligible

You will not qualify if you...

  • Insufficient pathological material from surgery for routine diagnosis and study use
  • Lack of definitive pathological diagnosis of primary supratentorial glioblastoma as per 2021 WHO classification

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fondazione Policlinico Universitario A. Gemelli IRCCS

Rome, Italy, 00168

Actively Recruiting

Loading map...

Research Team

Q

Quintino Giorgio D'Alessandris, MD, PhD

CONTACT

R

Roberto Pallini, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma | DecenTrialz